At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
Pembrolizumab +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Personalized, Randomized, Phase 2 Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Patient Observation, and 1 other intervention for Oral Cavity Carcinoma and Oral Intraepithelial Neoplasia. Completed, enrolled 15 participants across 1 site.
Detailed Summary
This randomized phase II trial studies how well pembrolizumab works in treating patients with high risk oral intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartJun 2017
Primary CompletionJul 2025
TodayJul 2026
First PostedAug 29, 2016
Enrollment StartJun 14, 2017
Primary CompletionJul 14, 2025
TodayJul 2, 2026
Enrollment to primary: 8.1 yearsPosted 9.8 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Patient Observationother
Undergo observation
Pembrolizumabbiological
Given IV